JP6550370B2 - 脂質レベルを低下させるロイシンおよびニコチン酸 - Google Patents

脂質レベルを低下させるロイシンおよびニコチン酸 Download PDF

Info

Publication number
JP6550370B2
JP6550370B2 JP2016502254A JP2016502254A JP6550370B2 JP 6550370 B2 JP6550370 B2 JP 6550370B2 JP 2016502254 A JP2016502254 A JP 2016502254A JP 2016502254 A JP2016502254 A JP 2016502254A JP 6550370 B2 JP6550370 B2 JP 6550370B2
Authority
JP
Japan
Prior art keywords
nicotinic acid
composition
leucine
metabolites
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516040A (ja
JP2016516040A5 (https=
Inventor
マイケル ジメル，
マイケル ジメル，
アンチェ ブルックバウアー，
アンチェ ブルックバウアー，
Original Assignee
ニューサート サイエンシーズ， インコーポレイテッド
ニューサート サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューサート サイエンシーズ， インコーポレイテッド, ニューサート サイエンシーズ， インコーポレイテッド filed Critical ニューサート サイエンシーズ， インコーポレイテッド
Publication of JP2016516040A publication Critical patent/JP2016516040A/ja
Publication of JP2016516040A5 publication Critical patent/JP2016516040A5/ja
Application granted granted Critical
Publication of JP6550370B2 publication Critical patent/JP6550370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
JP2016502254A 2013-03-15 2014-03-13 脂質レベルを低下させるロイシンおよびニコチン酸 Expired - Fee Related JP6550370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800363P 2013-03-15 2013-03-15
US61/800,363 2013-03-15
PCT/US2014/026816 WO2014152016A1 (en) 2013-03-15 2014-03-13 Leucine and nicotinic acid reduces lipid levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019016877A Division JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Publications (3)

Publication Number Publication Date
JP2016516040A JP2016516040A (ja) 2016-06-02
JP2016516040A5 JP2016516040A5 (https=) 2017-04-13
JP6550370B2 true JP6550370B2 (ja) 2019-07-24

Family

ID=51581094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502254A Expired - Fee Related JP6550370B2 (ja) 2013-03-15 2014-03-13 脂質レベルを低下させるロイシンおよびニコチン酸
JP2019016877A Pending JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019016877A Pending JP2019065049A (ja) 2013-03-15 2019-02-01 脂質レベルを低下させるロイシンおよびニコチン酸

Country Status (16)

Country Link
US (5) US9585876B2 (https=)
EP (1) EP2968333B1 (https=)
JP (2) JP6550370B2 (https=)
KR (1) KR20150130455A (https=)
CN (1) CN105228627B (https=)
AU (1) AU2014236687A1 (https=)
BR (1) BR112015023310A2 (https=)
CA (1) CA2902879C (https=)
HK (1) HK1219660A1 (https=)
IL (1) IL240762B (https=)
MX (1) MX2015011195A (https=)
PH (1) PH12015502033A1 (https=)
RU (1) RU2015143836A (https=)
SG (1) SG11201507046UA (https=)
WO (1) WO2014152016A1 (https=)
ZA (4) ZA201506481B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3197437A4 (en) * 2014-09-24 2018-05-23 NuSirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
WO2016149395A1 (en) 2015-03-16 2016-09-22 ChromaDex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
US20190262291A1 (en) * 2016-07-19 2019-08-29 Roland W. Winterfield Methods and compositions for alleviating myopathy
WO2018075867A1 (en) * 2016-10-21 2018-04-26 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) AND PROBIOTICS
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
WO2019108878A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
WO2019133815A1 (en) * 2017-12-28 2019-07-04 Kansas State University Research Foundation Nicotinamide riboside treatments of domesticated meat animals
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN116019780B (zh) * 2021-10-26 2024-09-24 成都拂尔医药科技有限公司 一种双黄纳米颗粒及其制备与应用
CN121793959A (zh) 2023-06-14 2026-04-03 可劳迈戴斯有限公司 静脉内配制品中的烟酰胺核苷及其衍生物与使用方法

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
DE69723812D1 (de) 1996-01-09 2003-09-04 Riken Wako Aminosäurezusammensetzungen
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE69707413T3 (de) 1997-01-09 2009-07-02 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
HUP0101890A2 (hu) 1998-05-04 2001-10-28 Andreas Johannes Kesel Monomer, oligomer és polimer knoevenagel-kondenzációs termékek
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
JP2003529347A (ja) 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US8398546B2 (en) 2000-06-16 2013-03-19 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
ES2311482T3 (es) 2000-12-29 2009-02-16 Martin Francis Gannon Producto alimenticio para animales.
PL363426A1 (en) 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
CA2466415C (en) 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
AU2003275491A1 (en) 2002-10-09 2004-05-04 Bodymedia, Inc. Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
AU2004221875B2 (en) 2003-03-13 2010-11-11 Vector Usa Inc. A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
JP2006520335A (ja) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
JP4353982B2 (ja) 2003-05-14 2009-10-28 インダス バイオテック ピーブイティ． エルティーディー． 糖尿病処置用相乗作用組成物
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
US7502643B2 (en) 2003-09-12 2009-03-10 Bodymedia, Inc. Method and apparatus for measuring heart related parameters
ATE547951T1 (de) 2003-11-03 2012-03-15 Hills Pet Nutrition Inc Überzogene tierfutterzusammensetzung
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
EP1685833A1 (en) 2003-11-21 2006-08-02 Ajinomoto Co., Inc. Remedy for diabetes
CN1886061B (zh) 2003-11-26 2011-11-16 希尔氏宠物营养品公司 减少伴侣动物排泄物气味的方法
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
CA2569015A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2588818A1 (en) 2004-11-29 2006-06-01 Toyo Shinyaku Co., Ltd. Athletic ability enhancing composition
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
PL1845994T3 (pl) 2005-02-11 2009-07-31 Pulmagen Therapeutics Synergy Kombinacja związków metyloksantyny i steroidów do leczenia przewlekłych chorób układu oddechowego
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
JP2008535790A (ja) 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
ES2376114T3 (es) 2005-05-13 2012-03-09 Nestec S.A. Producción de glucosamina a partir de especies vegetales.
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070092577A1 (en) 2005-10-03 2007-04-26 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
AU2006320167C1 (en) 2005-12-02 2011-04-07 Hill's Pet Nutrition, Inc. Methods for altering stool quality and/or stool frequency
BRPI0706448A2 (pt) 2006-01-10 2011-03-29 Hills Pet Nutrition Inc método, composição e kit para promover perda de gordura em um animal adulto, meio para comunicar informação sobre ou instruções para usar uma dieta, e, uso de lisina
WO2007100722A2 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2015644A1 (en) 2006-05-10 2009-01-21 DSMIP Assets B.V. Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) * 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
CA2672420A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
CA2675638C (en) 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
EP2126828A4 (en) 2007-02-16 2012-01-25 Bodymedia Inc SYSTEMS AND METHODS FOR UNDERSTANDING AND APPLYING THE PHYSIOLOGICAL AND CONTEXTUAL LIFE PATTERNS OF ONE OR MORE INDIVIDUALS
ATE468025T1 (de) 2007-02-23 2010-06-15 Hills Pet Nutrition Inc Zusammensetzungen und verfahren für die gewichtskontrolle bei tieren
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
JPWO2008143182A1 (ja) 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
WO2008153945A2 (en) 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
US8088043B2 (en) 2007-09-07 2012-01-03 Nike, Inc. Wearable device assembly having athletic functionality
WO2009054994A2 (en) 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
RU2440771C1 (ru) 2007-12-21 2012-01-27 Хилл'С Пет Ньютришн, Инк. Состав кормового продукта для домашних животных (варианты)
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MX2010008376A (es) 2008-02-04 2011-02-22 Mercury Therapeutics Inc Moduladores ampk.
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
AU2009225721B2 (en) 2008-03-17 2014-02-13 The Procter & Gamble Company. User-customizable dosing system
JP5645809B2 (ja) 2008-04-02 2014-12-24 ナイキ イノベイト セー． フェー． 運動用機能を有するウェアラブルデバイスアセンブリ
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
AU2009282482B2 (en) 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism
AU2009322474A1 (en) 2008-12-01 2011-07-21 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CA2760158C (en) 2009-04-26 2016-08-02 Nike International Ltd. Gps features and functionality in an athletic watch system
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
JP2013500010A (ja) 2009-07-21 2013-01-07 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 愛玩動物の栄養系
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2477620A1 (en) 2009-09-18 2012-07-25 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
AU2010343129B2 (en) 2009-12-29 2013-05-16 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
CN102695428A (zh) 2010-01-06 2012-09-26 雀巢产品技术援助有限公司 用于模拟热量限制的膳食方案
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
EP2564858A4 (en) 2010-04-28 2013-10-30 Nihon Pharmaceutical Co Ltd COMPOSITION FOR THE TREATMENT OF ASTHENOPIA
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
HK1199378A1 (en) 2011-08-19 2015-07-03 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
WO2014149280A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
EP3054940B1 (en) 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis

Also Published As

Publication number Publication date
EP2968333A4 (en) 2016-11-02
US9408834B2 (en) 2016-08-09
KR20150130455A (ko) 2015-11-23
JP2016516040A (ja) 2016-06-02
JP2019065049A (ja) 2019-04-25
ZA201506481B (en) 2017-08-30
US9585876B2 (en) 2017-03-07
CA2902879A1 (en) 2014-09-25
IL240762A0 (en) 2015-10-29
US9895357B2 (en) 2018-02-20
IL240762B (en) 2018-11-29
EP2968333B1 (en) 2022-01-12
MX2015011195A (es) 2016-03-11
EP2968333A1 (en) 2016-01-20
ZA201705790B (en) 2018-12-19
ZA201805629B (en) 2019-11-27
US20180214421A1 (en) 2018-08-02
ZA201606052B (en) 2018-05-30
BR112015023310A2 (pt) 2017-07-18
HK1219660A1 (zh) 2017-04-13
RU2015143836A (ru) 2017-04-27
US20160008329A1 (en) 2016-01-14
US9707213B2 (en) 2017-07-18
US20170340615A1 (en) 2017-11-30
SG11201507046UA (en) 2015-10-29
CA2902879C (en) 2023-09-26
WO2014152016A1 (en) 2014-09-25
US20170000780A1 (en) 2017-01-05
US20150056274A1 (en) 2015-02-26
PH12015502033A1 (en) 2016-01-18
AU2014236687A1 (en) 2015-09-10
CN105228627B (zh) 2018-07-13
CN105228627A (zh) 2016-01-06

Similar Documents

Publication Publication Date Title
JP6550370B2 (ja) 脂質レベルを低下させるロイシンおよびニコチン酸
US20180235917A1 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
CN106456997B (zh) 用于减少或预防肝性脂肪变性的组合物和方法
EP3130336A1 (en) Food and/or nutraceutical composition containing pea
CN105101958B (zh) 治疗肺病状
Fukumitsu et al. Maslinic acid in olive fruit alleviates mild knee joint pain and improves quality of life by promoting weight loss in the elderly
CN109090611A (zh) 一种AGEs抑制组合物及其应用、制备方法、制剂
US20260076986A1 (en) A combination of scyllo-inositol and flavones
US20220409647A1 (en) Compositions, methods and kits for altering adipocytes
RU2189243C1 (ru) Композиции "гинрозин", обладающие общеукрепляющим и адаптогенным действием
Tafti et al. Efficacy of herbal supplementation of purslane freeze-dried juice for weight loss: An 8-week randomized, double-blind, placebo-controlled clinical trial
Bilder et al. Over-the-counter medications, vitamins, minerals, biologicals, and herbal supplements
Abd Alkareem et al. Metformin and Omega 3 effect on Cholesterol and HDL level in Iraqi women with Poly Cystic Ovary Syndrome
Asaab Development of composition and technology of tablets with Rhodiola rosea extract
Hossain et al. Recent Advancement in the Use of Nano-Nutraceuticals in Medicine
WO2026047693A1 (en) Synergistic nutraceutical composition to improve cardio-metabolic health
WO2025254861A1 (en) A combination of scyllo-inositol and n-acetyl cysteine and related compounds
Vlachou et al. Vitamin C Fast Action Tablets by Doctor's Formulas' Food Supplements: Evaluation of Matrix Properties
Mullaicharam et al. EVIDENCE-BASED PRACTICE OF GINKGO BILOBA IN BRAIN HEALTH: AREVIEW
TWM593866U (zh) 口服錠
CN109152805A (zh) 用于治疗和预防类风湿性关节炎的组合物
Marihal Preparation and evaluation of chewable tablet used as a nutraceutical for osteoarthritis
AU2017327889A1 (en) Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190701

R150 Certificate of patent or registration of utility model

Ref document number: 6550370

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees